Non-Small Cell Lung Cancer Treatment Options

Novel HER1/EGFR-Targeted Agents for Non-Small Cell Lung Cancer: Current State of the Art

(The following articles were gathered from MedScape from WebMD )

  • Targeting HER1/EGFR to Improve Outcomes for Patients With Non-Small Cell Lung Cancer (7/27/04)

by Ulrich Gatzemeier, MD
* Use of Biologic Agents for Non-Small Cell Lung Cancer
* Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
* Pivotal Trial Data With Erlotinib
* Non-Small Cell Lung Cancer: The Future

by Manuel Hidalgo, MD
* Properties of Erlotinib
* Erlotinib and Kinase Activation
* Experimental Data on Erlotinib
* Use of Erlotinib in Combination
* Erlotinib and Epidermal Growth Factor Receptor Variant III

by Alan Sandler, MD
* Erlotinib Phase I Monotherapy Studies
* Erlotinib Phase I Combination Studies
* Erlotinib Phase II Trial: Study Background
* Erlotinib Phase II Trial: Study Findings
* Erlotinib Phase II Trial in Bronchioloalveolar Cell Carcinoma: Study Background
* Erlotinib Phase II Trial in Bronchioloalveolar Cell Carcinoma: Study Findings
* Phase I/II Trial of Erlotinib Plus Bevacizumab: Study Background
* Phase I/II Trial of Erlotinib Plus Bevacizumab: Study Findings
* Phase III Trials in Non-Small Cell Lung Cancer

by Roman Perez-Soler, MD
* Skin-Associated Toxicity and Epidermal Growth Factor Receptor
* Rash in Phase II Studies of Epidermal Growth Factor Receptor-Targeted Agents
* Survival by Grade of Rash in Trials of Erlotinib
* Survival by Grade of Rash With Other Agents
* Severity of Rash and Pharmacokinetic Parameters

  • Other Candidate Predictive and Surrogate Markers of Antitumor Activity (7/27/04)

by Denis Soulieres, MD
* Prognostic Markers for Non-Small Cell Lung Cancer: Factors Identified From Microarray
* Predictive and Surrogate Markers of Response: Statistical and Clinical Considerations
* Complex Molecular Interactions: Looking at the Model
* Target Characteristics to Define Predictive and Surrogate Markers
* Characterizing the Signaling Pathways to Determine Response
* Assessing Determinants of Resistance
* Host Characteristics to Define Predictive and Surrogate Markers

Advanced Non-Small-Cell Lung Cancer: Focusing on the Therapeutic Horizon in 2004 (7/27/04)

  • Summary: Although epidermal growth factor receptor (EGFR) inhibition has not yet shown a benefit in the front-line setting in patients with advanced non-small-cell lung cancer (NSCLC), a critical, pace-setting phase 3 trial presented at the American Society of Clinical Oncology (ASCO) 2004 meeting has rejuvenated our enthusiasm.

C. Gridelli, et al, "Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel" Annals of Oncology 12:419-426, 2004 (Posted 7/27/04)

  • Summary: On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options.

Handra P. Belani, et al, "First-line chemotherapy for NSCLS: an overview of relevant trials" Lung Cancer 38 (2002) S13-S19 (Posted 7/27/04)

  • Summary: This paper reviews data on efficacy and toxicity drawn from teh wide range of trials that have investigated alternative monotherapies and two- and three-drug regimens. It also includes detailed presentation of results from TAX 326, the only trial to date that demonstrates a significant advantage for one new agent/platinum combination over another.

Cancer Advances: News from the 2004 ASCO Annual Meeting: Drug Shows Activity in Advanced BAC (6/9/04)

Ethyol® Protects Against Side Effects of Treatment in Non-Small Cell Lung Cancer (9/23/2003)

Next Era of Cancer Therapy Aims to Separate Cancer From Blood Supply (5/19/03)

* * * * * * * * * * *
Neither the Law Offices of Roger G. Worthington nor its clients herein (including clients of other law firms) intend to waive the attorney-client privilege by posting information about these clients herein. The information contained herein is intended to educate and inform asbestos cancer patients and their families of potential medical and legal options. Roger Worthington is not a medical doctor. Patients are advised to consult with a medical doctor and/or an attorney if they have questions regarding this information. The opinions expressed herein by persons other than Roger Worthington are not necessarily endorsed by the Law Offices of Roger G. Worthington, P.C. This is an open forum.

* * * * * * * * * * *